These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 23026686)

  • 1. Re: cost-effectiveness of pertussis booster vaccination in the Netherlands.
    O'Mahony JF
    Vaccine; 2012 Nov; 30(50):7141. PubMed ID: 23026686
    [No Abstract]   [Full Text] [Related]  

  • 2. Response on "RE: Cost-effectiveness of pertussis booster vaccination in the Netherlands".
    Rozenbaum MH; Postma MJ
    Vaccine; 2013 Apr; 31(16):2024. PubMed ID: 23246308
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-effectiveness of pertussis booster vaccination in the Netherlands.
    Rozenbaum MH; De Cao E; Postma MJ
    Vaccine; 2012 Nov; 30(50):7327-31. PubMed ID: 22749838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conclusions on (cost-)effectiveness of pertussis booster vaccination strategies highly dependent on selections made in evidence review.
    Postma MJ; de Vries R; Roord J
    Vaccine; 2009 Dec; 27(52):7242-3. PubMed ID: 19744583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A critical literature review of health economic evaluations in pertussis booster vaccination.
    Millier A; Aballea S; Annemans L; Toumi M; Quilici S
    Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):71-94. PubMed ID: 22280198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and economic assessment of different general population strategies of pertussis vaccine booster regarding number of doses and age of application for reducing whooping cough disease burden: a systematic review.
    Rodríguez-Cobo I; Chen YF; Olowokure B; Litchfield I
    Vaccine; 2008 Dec; 26(52):6768-76. PubMed ID: 18835414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic analysis of pertussis illness in the Dutch population: implications for current and future vaccination strategies.
    de Greeff SC; Lugnér AK; van den Heuvel DM; Mooi FR; de Melker HE
    Vaccine; 2009 Mar; 27(13):1932-7. PubMed ID: 19368774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis.
    Purdy KW; Hay JW; Botteman MF; Ward JI
    Clin Infect Dis; 2004 Jul; 39(1):20-8. PubMed ID: 15206048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The burden of pertussis in older adults: what is the role of vaccination? A systematic literature review.
    Kandeil W; Atanasov P; Avramioti D; Fu J; Demarteau N; Li X
    Expert Rev Vaccines; 2019 May; 18(5):439-455. PubMed ID: 30887849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of various pertussis vaccination strategies primarily aimed at protecting infants in the Netherlands.
    Westra TA; de Vries R; Tamminga JJ; Sauboin CJ; Postma MJ
    Clin Ther; 2010 Aug; 32(8):1479-95. PubMed ID: 20728761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pertussis in the Netherlands].
    de Greeff SC; de Melker HE; Mooi FR
    Ned Tijdschr Geneeskd; 2010; 154():A1383. PubMed ID: 20170575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Booster vaccination after neonatal priming with acellular pertussis vaccine.
    Knuf M; Schmitt HJ; Jacquet JM; Collard A; Kieninger D; Meyer CU; Siegrist CA; Zepp F
    J Pediatr; 2010 Apr; 156(4):675-8. PubMed ID: 20303444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Community awareness and predictors of uptake of pertussis booster vaccine in South Australian adults.
    Clarke M; Thomas N; Giles L; Marshall H
    Vaccine; 2015 Dec; 33(51):7337-7343. PubMed ID: 26514422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bordetella pertussis and pertussis vaccines.
    Guiso N
    Clin Infect Dis; 2009 Nov; 49(10):1565-9. PubMed ID: 19839747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of a prepregnancy pertussis booster dose on maternal antibody titers in young infants.
    Leuridan E; Hens N; Peeters N; de Witte L; Van der Meeren O; Van Damme P
    Pediatr Infect Dis J; 2011 Jul; 30(7):608-10. PubMed ID: 21206396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Time for booster doses against whooping cough for 10-year-old children].
    Carlsson RM; Ekholm L; Gothefors L; Granström M; Trolin I; Tegnell A
    Lakartidningen; 2005 Aug 29-Sep 4; 102(35):2394-8. PubMed ID: 16184889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale for pertussis booster vaccination throughout life in Europe.
    Zepp F; Heininger U; Mertsola J; Bernatowska E; Guiso N; Roord J; Tozzi AE; Van Damme P
    Lancet Infect Dis; 2011 Jul; 11(7):557-70. PubMed ID: 21600850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of next-generation vaccines: The case of pertussis.
    Fitzpatrick MC; Wenzel NS; Scarpino SV; Althouse BM; Atkins KE; Galvani AP; Townsend JP
    Vaccine; 2016 Jun; 34(29):3405-11. PubMed ID: 27087151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of adolescent pertussis vaccination for the Netherlands: using an individual-based dynamic model.
    de Vries R; Kretzschmar M; Schellekens JF; Versteegh FG; Westra TA; Roord JJ; Postma MJ
    PLoS One; 2010 Oct; 5(10):e13392. PubMed ID: 20976213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of targeted vaccination to protect new-borns against pertussis: comparing neonatal, maternal, and cocooning vaccination strategies.
    Lugnér AK; van der Maas N; van Boven M; Mooi FR; de Melker HE
    Vaccine; 2013 Nov; 31(46):5392-7. PubMed ID: 24075918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.